NR4A1 and breast carcinoma: For women with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative (HR+/HER2−) advanced breast cancer (ABC), CDK4/6 inhibitors in combination with endocrine therapy (ET) have become the standard of care [6,7].